CPMG Inc

Q2 2018 13F Combination Report, Restatement, Stock Holdings

Signature - Title
John E. Bateman - Chief Operating Officer
Location
Dallas, TX
Holdings as of
June 30, 2018
Value $
$208M
Num holdings
15
Date filed
10/2/2018, 04:18 PM
Description
A portion of the US holdings for this investor are reported in this report and a portion are reported by other reporting manager(s). The Form 13F report requires disclosure of the manager that files the report, the name and class of the security, the CUSIP code, the number of shares as of the end of the calendar quarter for which the report is filed, and the total market value. The market value column should not be used as a substitute for Assets Under Management (AUM), as it does not include cash held in accounts.
Previous filing
Q1 2018 - Oct 2, 2018
Next filing
Q3 2018 - Nov 14, 2018
Options Holdings
Showing stock holdings, see here for options holdings
Sym Weight Trade Impact Company Class Shares Change Activity Value Change $ Value $ * Price $ Shares Principal
Filing 2018 Q2 - Restatement compared to 2018 Q1 - Restatement by default.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.

Person Signing this Report on Behalf of Reporting Manager:

Name Title City, State Date
John E. Bateman Chief Operating Officer Dallas, Texas 10/2/2018

This Amendment Number 1 is being filed to restate the position information in Reata Pharmaceuticals, Inc. ("Reata"). The Form 13F-HR filed on August 14, 2018 inadvertently reported the position information for Reata as the total of Class A and Class B shares over which CPMG, Inc. ("CPMG") had investment discretion as of June 30, 2018. This Amendment Number 1 includes only the reportable 2,912,523 Class A shares over which CPMG had investment discretion as of June 30, 2018. This Amendment Number 1 does not include the 1,692,857 Class B shares of Reata over which CPMG had investment discretion as of June 30, 2018 because such Class B shares were not included in the relevant quarter's Official List of Section 13(f) Securities, and thus should be excluded.